首页 > 市场调查报告书 > 医疗设备

心血管设备

市场调查报告书

商品编码

1956384

左心室辅助装置市场报告：趋势、预测与竞争分析（至2031年）

Left Ventricular Assist Device Market Report: Trends, Forecast and Competitive Analysis to 2031

出版日期: 2026年02月25日 | 出版商:

Lucintel | 英文 150 Pages | 商品交期: 3个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

简介目录

全球左心室辅助装置（LVAD）市场预计将从2025年到2031年以9.2%的复合年增长率成长。该市场的主要驱动因素是心血管疾病的日益普遍、对先进心臟衰竭治疗方法需求的不断增长以及微创手术的日益普及。

根据 Lucintel 的预测，目的地治疗在预测期内有望实现高速成长。
从应用角度来看，医院预计将呈现更高的成长率。
从区域来看，预计亚太地区在预测期内将达到最高的成长率。

左心室辅助装置市场的新趋势

受技术进步、心臟衰竭患者数量不断增长以及患者需求变化等因素的推动，左心室辅助装置（LVAD）市场正经历快速成长。随着医疗服务提供者寻求更有效、更持久的晚期心臟衰竭管理解决方案，创新装置和策略层出不穷。这些趋势正在改变LVAD治疗格局，使其更加便利、更有效率且以患者为中心。对于希望掌握市场机会并改善患者预后的利害关係人相关人员，了解这些发展至关重要。以下关键趋势突显了将塑造左心室辅助装置市场未来发展的重大变化。

设备小型化：左心室辅助装置（LVAD）小型化、紧凑化的发展趋势旨在提高患者舒适度并降低手术风险。材料和工程技术的进步使得植入创伤更小、更易于管理的设备得以研发。小型化的LVAD有助于更广泛的患者群体，包括体型较小和併发症的患者。这项发展将改善患者的生活质量，缩短住院时间，降低併发症率，最终促进市场扩张并改善患者预后。
无线技术的应用日益广泛：将无线监测和控制系统与左心室辅助装置（LVAD）结合，正在革新患者管理方式。无线技术能够实现即时资料传输、远端监测以及无需侵入性操作即可调整设备。这一趋势提高了病患安全性，减少了就医次数，并有助于主动管理併发症。此外，它还促进了远端医疗的发展，使LVAD治疗更加便捷易行，这在新冠疫情期间尤其重要，并有助于设备的长期维护。
全植入式装置的研发：向全植入式辅助装置（LVAD）的过渡旨在消除外部驱动线，从而显着降低感染风险并提高患者舒适度。这些装置采用无线电力传输和先进的电池系统，增强了患者的活动能力和生活品质。全植入式LVAD降低了驱动线感染（一种主要併发症）的风险，并简化了术后护理。这项创新有望扩大LVAD疗法的应用范围，并改善患者的长期预后。
聚焦生物相容性和耐用材料：生物材料的进步正在延长设备的使用寿命并减少不良反应。研究人员正在开发生物相容性表面，以最大限度地减少血栓形成和炎症，从而降低抗凝血治疗的需求。耐用材料能够延长设备的使用寿命，减少更换频率和相关风险。这些改进对于末期心臟衰竭患者的长期支持至关重要，能够提高左心室辅助装置（LVAD）的安全性和可靠性，并扩大其市场潜力。
左心室辅助装置（LVAD）作为最后手段的应用日益增加：目前，LVAD正逐渐成为永久性解决方案，或称为最后手段。随着设备耐用性和患者管理水平的提高，越来越多的患者接受LVAD作为长期治疗，而不仅仅是作为心臟移植的过渡手段。这一转变的驱动因素是供体心臟短缺以及晚期心臟衰竭患者数量的增加。这扩大了市场覆盖范围，促进了创新，并强调了提高患者生活品质的重要性，最终使LVAD从临时解决方案转变为永久性解决方案。

总而言之，这些新兴趋势正在重塑左心室辅助装置市场，使装置更加人性化、技术先进、适合长期使用，扩大患者群体，减少併发症，改善整体疗效，从而推动机械循环支持领域的市场成长和创新。

左心室辅助装置市场近期趋势

左心室辅助装置市场正经历显着的进步，这主要得益于技术创新、患者需求的成长以及适应症的扩大。全球范围心臟衰竭盛行率的不断上升，推动了对耐用且有效的机械循环支援装置的需求。近期趋势表明，市场关注的重点在于提升装置性能、患者安全性和整体治疗效果。这些创新正在重塑左心室辅助装置市场的未来，使更多患者能够更便利、更可靠地使用此类装置。以下关键发展将重点放在这个充满活力的市场目前的发展方向和变革性变化。

技术创新：新型左心室辅助装置 (LVAD) 使用更小、更耐用的组件，减少感染疾病和机械故障等併发症，提高患者的生活品质和装置使用寿命。
生物相容性材料：生物相容性材料的进步最大限度地减少了血栓形成和溶血，降低了血栓性栓塞症的风险，并减少了抗凝血治疗的需要。
远端监控功能：远端监控系统使临床医生能够即时追踪设备性能和患者健康状况，从而实现主动管理并降低再入院率。
适应症扩大：越来越多的证据支持在心臟衰竭早期阶段使用左心室辅助装置 (LVAD)，从而扩大了终末期疾病以外的患者群体，并加速了市场渗透。
监管核准和报销：近期的核准和有利的报销政策正在加速 LVAD 的采用，并鼓励製造商进行创新和扩展其产品系列。

这些发展正透过提高设备安全性、扩大病患覆盖范围和改善临床疗效，共同改变左心室辅助装置市场。因此，在技术进步和临床实践不断发展的推动下，该市场有望实现持续成长。

The future of the global left ventricular assist device market looks promising with opportunities in the hospital and clinic markets. The global left ventricular assist device market is expected to grow with a CAGR of 9.2% from 2025 to 2031. The major drivers for this market are the increasing prevalence of cardiovascular diseases, the rising demand for advanced heart failure treatments, and the growing adoption of minimally invasive surgeries.

Lucintel forecasts that, within the type category, destination therapy is expected to witness higher growth over the forecast period.
Within the application category, hospital is expected to witness higher growth.
In terms of region, APAC is expected to witness the highest growth over the forecast period.

Emerging Trends in the Left Ventricular Assist Device Market

The left ventricular assist device market is experiencing rapid growth driven by technological advancements, increasing prevalence of heart failure, and evolving patient needs. As healthcare providers seek more effective and durable solutions for managing advanced heart failure, innovative devices and strategies are emerging. These trends are transforming the landscape of LVAD therapy, making it more accessible, efficient, and patient-centric. Understanding these developments is crucial for stakeholders aiming to capitalize on market opportunities and improve patient outcomes. The following key trends highlight the major shifts shaping the future of the left ventricular assist device market.

Miniaturization of Devices: The trend toward smaller, more compact LVADs aims to improve patient comfort and reduce surgical risks. Advances in materials and engineering have enabled the development of devices that are less invasive to implant and easier to manage. Miniaturized LVADs also facilitate broader patient eligibility, including those with smaller body sizes or comorbidities. This evolution enhances quality of life, reduces hospital stays, and lowers complication rates, ultimately expanding the market and improving patient outcomes.
Increased Use of Wireless Technology: Integration of wireless monitoring and control systems in LVADs is revolutionizing patient management. Wireless technology allows real-time data transmission, remote monitoring, and device adjustments without invasive procedures. This trend enhances patient safety, reduces hospital visits, and enables proactive management of complications. It also facilitates telemedicine, especially important during the COVID-19 pandemic, and supports long-term device maintenance, making LVAD therapy more convenient and accessible.
Development of Fully Implantable Devices: The shift toward fully implantable LVADs aims to eliminate external drivelines, significantly reducing infection risks and improving patient comfort. These devices incorporate wireless power transfer and advanced battery systems, allowing patients greater mobility and quality of life. Fully implantable LVADs also decrease the risk of driveline infections, a major complication, and simplify post-implant care. This innovation is expected to broaden the adoption of LVAD therapy and improve long-term patient outcomes.
Focus on Biocompatible and Durable Materials: Advances in biomaterials are enhancing device longevity and reducing adverse reactions. Researchers are developing biocompatible surfaces that minimize blood clot formation and inflammation, decreasing the need for anticoagulation therapy. Durable materials extend device lifespan, reducing the frequency of replacements and associated risks. These improvements are critical for long-term support in end-stage heart failure patients, making LVADs safer and more reliable, and thus expanding their market potential.
Growing Adoption of Destination Therapy: The trend toward using LVADs as a permanent solution, or destination therapy, is gaining momentum. As device durability and patient management improve, more patients are receiving LVADs not just as a bridge to transplant but as a long-term therapy. This shift is driven by the shortage of donor hearts and the increasing number of patients with advanced heart failure. It broadens the market scope, encourages innovation, and emphasizes quality of life improvements, ultimately transforming LVADs from temporary to permanent solutions.

In summary, these emerging trends are reshaping the left ventricular assist device market by making devices more patient-friendly, technologically advanced, and suitable for long-term use. They are expanding the patient population, reducing complications, and improving overall outcomes, thereby driving market growth and innovation in the field of mechanical circulatory support.

Recent Developments in the Left Ventricular Assist Device Market

The left ventricular assist device market has experienced significant advancements driven by technological innovations, increasing patient demand, and expanding indications. As heart failure prevalence rises globally, the need for durable and effective mechanical circulatory support devices has intensified. Recent developments reflect a focus on improving device performance, patient safety, and overall outcomes. These innovations are shaping the future landscape of the left ventricular assist device market, making devices more accessible and reliable for a broader patient population. The following key developments highlight the current trajectory and transformative changes within this dynamic market.

Technological Innovation: New LVAD models feature smaller, more durable components, reducing complications such as infections and mechanical failures, thereby improving patient quality of life and device longevity.
Biocompatible Materials: Advances in biocompatible materials have minimized blood clot formation and hemolysis, decreasing the risk of thromboembolic events and reducing the need for anticoagulation therapy.
Remote Monitoring Capabilities: Incorporation of remote monitoring systems allows clinicians to track device performance and patient health in real-time, leading to proactive management and reduced hospital readmissions.
Expanded Indications: Growing evidence supports LVAD use in earlier stages of heart failure, broadening the patient pool and increasing market penetration beyond end-stage cases.
Regulatory Approvals and Reimbursements: Recent approvals and favorable reimbursement policies have facilitated faster adoption of LVADs, encouraging manufacturers to innovate and expand their product portfolios.

These developments are collectively transforming the left ventricular assist device market by enhancing device safety, expanding patient access, and improving clinical outcomes. As a result, the market is poised for sustained growth, driven by technological progress and evolving clinical practices.

Strategic Growth Opportunities in the Left Ventricular Assist Device Market

The left ventricular assist device market is experiencing rapid growth driven by technological advancements, increasing prevalence of heart failure, and expanding indications for device implantation. As healthcare providers seek more effective and durable solutions for managing advanced heart failure, various applications are emerging as key growth drivers. These opportunities are transforming patient care, improving survival rates, and expanding market reach across different regions. Understanding these growth avenues is essential for stakeholders aiming to capitalize on the evolving landscape and meet the rising demand for innovative cardiac support devices.

Heart Failure Management: The rising incidence of chronic heart failure is a primary driver. LVADs are increasingly used as a bridge to transplantation or as destination therapy, significantly improving patient survival and quality of life. This application is expected to see sustained growth due to technological improvements and broader acceptance among clinicians.
Bridge to Transplantation: LVADs serve as a critical interim solution for patients awaiting heart transplants. Advances in device durability and reduced complications are expanding their use, leading to increased transplant eligibility and better patient outcomes.
Destination Therapy: For patients ineligible for transplant, LVADs are becoming a long-term solution. Innovations in device design and management are enhancing device longevity and reducing adverse events, thereby expanding the patient pool and market size.
Post-Myocardial Infarction Support: LVADs are increasingly used to support patients recovering from severe myocardial infarctions with compromised ventricular function. This application helps stabilize patients and improve recovery prospects, opening new market segments.
Pediatric and Congenital Heart Disease: Growing focus on pediatric cardiac care is driving the development of smaller, more adaptable LVADs for children with congenital heart defects. This niche market is expected to grow as device technology advances and clinical experience increases.

In summary, these key growth opportunities are significantly impacting the left ventricular assist device market by broadening application scope, enhancing device performance, and improving patient outcomes. The market is poised for continued expansion as innovations address unmet needs and healthcare systems worldwide adopt these life-saving devices.

Left Ventricular Assist Device Market Driver and Challenges

The left ventricular assist device market is influenced by a variety of technological, economic, and regulatory factors. Advances in medical technology have led to more efficient and durable devices, expanding their application scope. Economic factors such as increasing healthcare expenditure and rising prevalence of heart failure drive demand. Regulatory frameworks ensure safety and efficacy but can also pose barriers to market entry. Additionally, demographic shifts, including aging populations, further propel market growth. However, challenges such as high costs, regulatory hurdles, and device-related complications must be addressed to sustain growth. Understanding these drivers and challenges is essential for stakeholders aiming to capitalize on market opportunities.

The factors responsible for driving the left ventricular assist device market include:

Technological Innovation: The continuous development of more compact, durable, and efficient LVADs enhances patient outcomes and broadens their applicability. Innovations such as wireless power transfer and miniaturization improve device performance and patient comfort. These advancements reduce complications like infections and mechanical failures, making LVADs a more viable long-term solution. As technology progresses, the market benefits from increased adoption by healthcare providers and patients seeking improved quality of life. The integration of remote monitoring and smart device features further boosts market growth by enabling better management and early detection of issues.
Rising Prevalence of Heart Failure: The increasing incidence of heart failure globally, driven by factors like hypertension, coronary artery disease, and lifestyle changes, significantly fuels demand for LVADs. As the condition becomes more prevalent, especially among aging populations, the need for advanced treatment options grows. LVADs serve as a bridge to transplantation or as destination therapy, providing life-saving support. The expanding patient pool encourages healthcare providers and manufacturers to invest in research, development, and distribution of these devices, thereby expanding market size and scope.
Economic Growth and Healthcare Expenditure: Growing healthcare budgets and increased spending on cardiovascular treatments support market expansion. Governments and private insurers are more willing to cover advanced therapies like LVADs due to their proven benefits in improving survival rates and quality of life. This financial backing facilitates wider adoption, especially in developed regions. Additionally, the rising affordability of medical devices and technological cost reductions contribute to increased accessibility. As economic conditions improve, more patients gain access to these life-saving devices, further propelling market growth.
Regulatory Approvals and Reimbursement Policies: Favorable regulatory pathways and supportive reimbursement policies are critical drivers. Regulatory agencies like the FDA and EMA have streamlined approval processes for innovative LVADs, encouraging manufacturers to introduce new products. Reimbursement policies that cover device costs reduce financial barriers for patients and healthcare providers, promoting adoption. Clear guidelines and approval standards also enhance confidence in device safety and efficacy. As regulatory frameworks evolve to accommodate technological advancements, the market experiences accelerated growth and wider acceptance across different regions.
Increasing Awareness and Patient Acceptance: Growing awareness about heart failure management and LVAD benefits encourages patient acceptance and demand. Educational campaigns and improved physician knowledge facilitate early diagnosis and treatment, leading to increased device implantation. Patient acceptance is also boosted by the improved quality of life and survival rates associated with LVAD therapy. As more patients and healthcare providers recognize the advantages of these devices, market penetration deepens, especially in emerging markets where awareness is still developing.

The challenges facing this left ventricular assist device market include:

High Costs and Reimbursement Limitations: The substantial costs associated with LVAD implantation, maintenance, and management pose significant barriers. These devices are expensive, and limited reimbursement options in certain regions restrict patient access. High costs can deter healthcare providers from adopting the technology widely, especially in low- and middle-income countries. Additionally, reimbursement policies vary, creating disparities in access and affordability. The financial burden on patients and healthcare systems hampers market growth and necessitates strategies to reduce costs and improve coverage.
Device-Related Complications: Despite technological advancements, LVADs are associated with complications such as infections, bleeding, thrombosis, and mechanical failures. These adverse events can lead to increased hospitalizations, additional surgeries, and reduced patient quality of life. Managing these complications requires ongoing medical attention and can significantly impact the overall success and acceptance of LVAD therapy. Addressing these challenges through improved device design and better patient management protocols is essential for market sustainability.
Regulatory and Clinical Trial Challenges: Navigating complex regulatory landscapes and conducting extensive clinical trials can delay product approvals and market entry. Stringent safety and efficacy standards require significant time and financial investment, which can hinder innovation and slow down the introduction of new devices. Additionally, variability in regulatory requirements across regions complicates global market expansion. Ensuring compliance while maintaining rapid development cycles remains a key challenge for manufacturers aiming to stay competitive and meet evolving standards.

In summary, the left ventricular assist device market is driven by technological innovations, increasing heart failure prevalence, supportive economic and regulatory environments, and rising awareness. However, high costs, device-related complications, and regulatory hurdles pose significant challenges. Balancing these factors will determine the markets future trajectory, with ongoing advancements and strategic solutions needed to maximize growth and improve patient outcomes.

List of Left Ventricular Assist Device Companies

Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. With these strategies left ventricular assist device companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the left ventricular assist device companies profiled in this report include-

AbioMed
Abbott
Medtronic
Berlin Heart
Jarvik Heart
Sun Medical Technology Research
ReliantHeart

Left Ventricular Assist Device Market by Segment

The study includes a forecast for the global left ventricular assist device market by type, application, and region.

Left Ventricular Assist Device Market by Type [Value from 2019 to 2031]:

BTT Therapy
Destination Therapy
Others

Left Ventricular Assist Device Market by Application [Value from 2019 to 2031]:

Hospitals
Clinics

Left Ventricular Assist Device Market by Region [Value from 2019 to 2031]:

North America
Europe
Asia Pacific
The Rest of the World

Country Wise Outlook for the Left Ventricular Assist Device Market

The left ventricular assist device market has experienced significant advancements driven by technological innovations, increasing prevalence of heart failure, and expanding clinical applications. As healthcare systems adapt to these changes, key players are investing in research and development to improve device performance, patient outcomes, and affordability. Regulatory approvals and strategic collaborations are also shaping the market landscape across major regions. The United States, China, Germany, India, and Japan are at the forefront of these developments, each contributing uniquely to the global growth trajectory of LVAD technology.

United States: The US market has seen rapid adoption of advanced LVADs, driven by high healthcare expenditure and a large patient base with advanced heart failure. Recent approvals of next-generation devices with improved durability and reduced complications have enhanced treatment options. The focus on minimally invasive procedures and remote monitoring technologies is also increasing, supported by favorable reimbursement policies and extensive clinical trials. Leading companies are expanding their product portfolios and investing in research to address unmet needs, further consolidating their market positions.
China: China's left ventricular assist device market is expanding due to rising cardiovascular disease prevalence and government initiatives to improve cardiac care. Local manufacturers are gaining ground by offering cost-effective devices, while international players are entering strategic partnerships to penetrate the market. Recent developments include the approval of domestically produced LVADs and increased investment in research and development. The government's focus on healthcare infrastructure and increasing awareness about advanced heart failure treatments is expected to drive future growth.
Germany: Germany remains a key European hub for LVAD technology, with a strong emphasis on clinical research and innovation. Recent advancements include the development of more durable and biocompatible devices, along with improvements in patient management protocols. The country benefits from a well-established healthcare system, enabling widespread adoption of LVADs for both bridge-to-transplant and destination therapy. Regulatory support and collaborations between academia and industry are fostering continuous innovation, positioning Germany as a leader in LVAD technology within Europe.
India: The Indian left ventricular assist device market is witnessing rapid growth due to increasing cardiovascular disease burden and improving healthcare infrastructure. Recent developments include the approval of affordable, locally manufactured LVADs and the expansion of specialized cardiac centers. Government initiatives aimed at enhancing cardiac care and increasing awareness are also contributing to market growth. Innovations focused on reducing device costs and improving patient outcomes are gaining traction, making LVAD therapy more accessible to a broader patient population.
Japan: Japan's left ventricular assist device market is characterized by high technological sophistication and a focus on patient quality of life. Recent advancements include the introduction of compact, lightweight devices with enhanced durability and biocompatibility. The country's aging population has increased demand for advanced heart failure treatments, prompting ongoing research and clinical trials. Japan's strong regulatory framework and collaboration between industry and academia support continuous innovation, positioning it as a leader in the development and adoption of cutting-edge LVAD solutions.

Features of the Global Left Ventricular Assist Device Market

Market Size Estimates: Left ventricular assist device market size estimation in terms of value ($B).
Trend and Forecast Analysis: Market trends (2019 to 2024) and forecast (2025 to 2031) by various segments and regions.
Segmentation Analysis: Left ventricular assist device market size by type, application, and region in terms of value ($B).
Regional Analysis: Left ventricular assist device market breakdown by North America, Europe, Asia Pacific, and Rest of the World.
Growth Opportunities: Analysis of growth opportunities in different types, applications, and regions for the left ventricular assist device market.
Strategic Analysis: This includes M&A, new product development, and competitive landscape of the left ventricular assist device market.

Analysis of competitive intensity of the industry based on Porter's Five Forces model.

This report answers following 11 key questions:

Q.1. What are some of the most promising, high-growth opportunities for the left ventricular assist device market by type (BTT therapy, destination therapy, and others), application (hospitals and clinics), and region (North America, Europe, Asia Pacific, and the Rest of the World)?
Q.2. Which segments will grow at a faster pace and why?
Q.3. Which region will grow at a faster pace and why?
Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
Q.5. What are the business risks and competitive threats in this market?
Q.6. What are the emerging trends in this market and the reasons behind them?
Q.7. What are some of the changing demands of customers in the market?
Q.8. What are the new developments in the market? Which companies are leading these developments?
Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
Q.11. What M&A activity has occurred in the last 5 years and what has its impact been on the industry?

1. Executive Summary

2. Market Overview

2.1 Background and Classifications
2.2 Supply Chain

3. Market Trends & Forecast Analysis

3.1 Macroeconomic Trends and Forecasts
3.2 Industry Drivers and Challenges
3.3 PESTLE Analysis
3.4 Patent Analysis
3.5 Regulatory Environment

4. Global Left Ventricular Assist Device Market by Type

4.1 Overview
4.2 Attractiveness Analysis by Type
4.3 BTT Therapy : Trends and Forecast (2019-2031)
4.4 Destination Therapy : Trends and Forecast (2019-2031)
4.5 Others : Trends and Forecast (2019-2031)

5. Global Left Ventricular Assist Device Market by Application

5.1 Overview
5.2 Attractiveness Analysis by Application
5.3 Hospitals : Trends and Forecast (2019-2031)
5.4 Clinics : Trends and Forecast (2019-2031)

6. Regional Analysis

6.1 Overview
6.2 Global Left Ventricular Assist Device Market by Region

7. North American Left Ventricular Assist Device Market

7.1 Overview
7.2 North American Left Ventricular Assist Device Market by Type
7.3 North American Left Ventricular Assist Device Market by Application
7.4 The United States Left Ventricular Assist Device Market
7.5 Canadian Left Ventricular Assist Device Market
7.6 Mexican Left Ventricular Assist Device Market

8. European Left Ventricular Assist Device Market

8.1 Overview
8.2 European Left Ventricular Assist Device Market by Type
8.3 European Left Ventricular Assist Device Market by Application
8.4 German Left Ventricular Assist Device Market
8.5 French Left Ventricular Assist Device Market
8.6 Italian Left Ventricular Assist Device Market
8.7 Spanish Left Ventricular Assist Device Market
8.8 The United Kingdom Left Ventricular Assist Device Market

9. APAC Left Ventricular Assist Device Market

9.1 Overview
9.2 APAC Left Ventricular Assist Device Market by Type
9.3 APAC Left Ventricular Assist Device Market by Application
9.4 Chinese Left Ventricular Assist Device Market
9.5 Indian Left Ventricular Assist Device Market
9.6 Japanese Left Ventricular Assist Device Market
9.7 South Korean Left Ventricular Assist Device Market
9.8 Indonesian Left Ventricular Assist Device Market

10. ROW Left Ventricular Assist Device Market

10.1 Overview
10.2 ROW Left Ventricular Assist Device Market by Type
10.3 ROW Left Ventricular Assist Device Market by Application
10.4 Middle Eastern Left Ventricular Assist Device Market
10.5 South American Left Ventricular Assist Device Market
10.6 African Left Ventricular Assist Device Market

11. Competitor Analysis

11.1 Product Portfolio Analysis
11.2 Operational Integration
11.3 Porter's Five Forces Analysis
- Competitive Rivalry
- Bargaining Power of Buyers
- Bargaining Power of Suppliers
- Threat of Substitutes
- Threat of New Entrants
11.4 Market Share Analysis

12. Opportunities & Strategic Analysis

12.1 Value Chain Analysis
12.2 Growth Opportunity Analysis
- 12.2.1 Growth Opportunity by Type
- 12.2.2 Growth Opportunity by Application
12.3 Emerging Trends in the Global Left Ventricular Assist Device Market
12.4 Strategic Analysis
- 12.4.1 New Product Development
- 12.4.2 Certification and Licensing
- 12.4.3 Mergers, Acquisitions, Agreements, Collaborations, and Joint Ventures

13. Company Profiles of the Leading Players Across the Value Chain

13.1 Competitive Analysis Overview
13.2 AbioMed
- Company Overview
- Left Ventricular Assist Device Market Business Overview
- New Product Development
- Merger, Acquisition, and Collaboration
- Certification and Licensing
13.3 Abbott
- Company Overview
- Left Ventricular Assist Device Market Business Overview
- New Product Development
- Merger, Acquisition, and Collaboration
- Certification and Licensing
13.4 Medtronic
- Company Overview
- Left Ventricular Assist Device Market Business Overview
- New Product Development
- Merger, Acquisition, and Collaboration
- Certification and Licensing
13.5 Berlin Heart
- Company Overview
- Left Ventricular Assist Device Market Business Overview
- New Product Development
- Merger, Acquisition, and Collaboration
- Certification and Licensing
13.6 Jarvik Heart
- Company Overview
- Left Ventricular Assist Device Market Business Overview
- New Product Development
- Merger, Acquisition, and Collaboration
- Certification and Licensing
13.7 Sun Medical Technology Research
- Company Overview
- Left Ventricular Assist Device Market Business Overview
- New Product Development
- Merger, Acquisition, and Collaboration
- Certification and Licensing
13.8 ReliantHeart
- Company Overview
- Left Ventricular Assist Device Market Business Overview
- New Product Development
- Merger, Acquisition, and Collaboration
- Certification and Licensing

14. Appendix

14.1 List of Figures
14.2 List of Tables
14.3 Research Methodology
14.4 Disclaimer
14.5 Copyright
14.6 Abbreviations and Technical Units
14.7 About Us
14.8 Contact Us

02-2729-4219

+886-2-2729-4219

License/价格

左心室辅助装置市场报告：趋势、预测与竞争分析（至2031年）

Left Ventricular Assist Device Market Report: Trends, Forecast and Competitive Analysis to 2031

目录

第一章执行摘要

第二章市场概览

第三章：市场趋势与预测分析

4. 全球左心室辅助装置市场（按类型划分）

5. 全球左心室辅助装置市场（依应用划分）

第六章区域分析

7. 北美左心室辅助装置市场

8. 欧洲左心室辅助装置市场

9. 亚太地区左心室辅助装置市场

10. 世界其他地区（ROW）左心室辅助装置市场

第十一章竞争分析

第十二章：机会与策略分析

第十三章：价值链中主要企业的概况

第十四章附录

Left Ventricular Assist Device Market by Type [Value from 2019 to 2031]:

Left Ventricular Assist Device Market by Application [Value from 2019 to 2031]:

Left Ventricular Assist Device Market by Region [Value from 2019 to 2031]:

This report answers following 11 key questions: